uniQure N.V. – LSE:0EE0.L
uniQure N.V. stock price today
uniQure N.V. stock price monthly change
uniQure N.V. stock price quarterly change
uniQure N.V. stock price yearly change
uniQure N.V. key metrics
Market Cap | 817.90M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -6.20 |
Revenue | 19.00M |
EBITDA | -244.25M |
Income | -296.86M |
Revenue Q/Q | 59.34% |
Revenue Y/Y | -82.72% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -1285.37% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeuniQure N.V. stock price history
uniQure N.V. stock forecast
uniQure N.V. financial statements
| Jun 2023 | 2.42M | -68.47M | -2827.17% |
|---|---|---|---|
| Sep 2023 | 1.40M | -89.57M | -6366.1% |
| Dec 2023 | 6.68M | -73.20M | -1094.42% |
| Mar 2024 | 8.48M | -65.61M | -773.34% |
| Sep 2025 | 24.38M | -39.39M | -161.59% |
|---|---|---|---|
| Dec 2025 | 13.89M | -47.40M | -341.15% |
| Mar 2026 | 6.50M | -52.86M | -812.21% |
| Mar 2026 | 8.24M | -55.55M | -673.64% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 942769000 | 589.44M | 62.52% |
|---|---|---|---|
| Sep 2023 | 871550000 | 602.76M | 69.16% |
| Dec 2023 | 831689000 | 624.01M | 75.03% |
| Mar 2024 | 770050000 | 623.29M | 80.94% |
| Jun 2023 | -56.99M | 45.83M | 370.13M |
|---|---|---|---|
| Sep 2023 | 38.91M | -314.06M | -7.59M |
| Dec 2023 | -49.54M | 59.56M | 46K |
| Mar 2024 | -60.57M | 63.98M | 0 |
uniQure N.V. alternative data
| Aug 2023 | 501 |
|---|---|
| Sep 2023 | 501 |
| Oct 2023 | 501 |
| Nov 2023 | 501 |
| Dec 2023 | 501 |
| Jan 2024 | 501 |
| Feb 2024 | 501 |
| Mar 2024 | 480 |
| Apr 2024 | 480 |
| May 2024 | 480 |
| Jun 2024 | 480 |
| Jul 2024 | 480 |
uniQure N.V. other data
-
What's the price of uniQure N.V. stock today?
One share of uniQure N.V. stock can currently be purchased for approximately $21.32.
-
When is uniQure N.V.'s next earnings date?
Unfortunately, uniQure N.V.'s (0EE0.L) next earnings date is currently unknown.
-
Does uniQure N.V. pay dividends?
No, uniQure N.V. does not pay dividends.
-
How much money does uniQure N.V. make?
uniQure N.V. has a market capitalization of 817.90M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 85.12% to 15.84M US dollars.
-
What is uniQure N.V.'s stock symbol?
uniQure N.V. is traded on the LSE under the ticker symbol "0EE0.L".
-
What is uniQure N.V.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of uniQure N.V.?
Shares of uniQure N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does uniQure N.V. have?
As Jul 2024, uniQure N.V. employs 480 workers.
-
When uniQure N.V. went public?
uniQure N.V. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is uniQure N.V.'s official website?
The official website for uniQure N.V. is uniqure.com.
-
How can i contact uniQure N.V.?
uniQure N.V. can be reached via phone at +31 20 240 6000.
uniQure N.V. company profile:
uniQure N.V.
uniqure.comLSE
480
Medical - Pharmaceuticals
Healthcare
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Amsterdam, 1105 BP
:
ISIN: NL0010696654
:
